Continuous Glucose Monitoring in the Intensive Care Unit During the COVID-19 Pandemic

Diabetes Care. 2021 Mar;44(3):847-849. doi: 10.2337/dc20-2219. Epub 2020 Dec 23.


Objective: Real-time continuous glucose monitoring (rtCGM) in critically ill hospitalized patients holds promise; however, real-world data are needed.

Research design and methods: We placed Dexcom G6 CGM on intensive care unit (ICU) patients at Montefiore Medical Center with confirmed coronavirus disease 2019 (COVID-19) infection and glycemic variability. We analyzed inpatient CGM accuracy using point-of-care (POC) glucose-CGM matched pairs and included patients for analysis regardless of clinical status.

Results: We included 11 patients with CGM: 8 on continuous insulin infusion (CII), 8 on vasopressors, 8 intubated, 4 on high-dose glucocorticoids, 6 on renal replacement therapy, and 2 with anasarca. Accuracy was 12.58% for mean and 6.3% for median absolute relative difference. CGM reduced POC testing by ∼60% for patients on CII.

Conclusions: In this real-world preliminary analysis of rtCGM during critical illness, we demonstrate early feasibility, considerable accuracy, and meaningful reduction in the frequency of POC glucose testing.

MeSH terms

  • Adult
  • Aged
  • Blood Glucose / analysis*
  • COVID-19*
  • Critical Care
  • Critical Illness / therapy
  • Female
  • Humans
  • Insulin / therapeutic use
  • Insulin Infusion Systems
  • Intensive Care Units*
  • Male
  • Middle Aged
  • Pandemics
  • Point-of-Care Systems
  • SARS-CoV-2


  • Blood Glucose
  • Insulin